Dermatology online journal最新文献

{"title":"Blurry vision to clear outcomes: Treatment challenges in eccrine hidrocystomas.","authors":"Barinder Beenu Bajwa, Colton Jensen, Eunice Y Chow","doi":"10.25251/n41i1lo8","DOIUrl":"https://doi.org/10.25251/n41i1lo8","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GZ21T as an emerging topical dermatologic therapy: A literature review.","authors":"Kritin K Verma, Jesse Salas, Angelica Zambrano, Cameron E West","doi":"10.25251/nke1113l","DOIUrl":"10.25251/nke1113l","url":null,"abstract":"<p><strong>Background: </strong>Chronic and treatment-resistant dermatologic disorders remain difficult to manage with current therapies because of incomplete efficacy, tolerability limitations, and long-term safety concerns. GZ21T is a topical formulation of curcumin, harmine, and isovanillin that has emerged as a potential novel therapy for inflammatory and neoplastic skin disease.</p><p><strong>Objective: </strong>To review the preclinical evidence, proposed mechanism of action, safety data, and future clinical potential of GZ21T in atopic dermatitis, mycosis fungoides, and actinic keratoses.</p><p><strong>Methods: </strong>A focused literature review was performed using published preclinical and early translational studies evaluating GZ17-6.02 and topical GZ21T in dermatologic disease models, including atopic dermatitis, mycosis fungoides, and actinic keratoses. Studies were included if they reported mechanistic, efficacy, or safety outcomes relevant to dermatologic application; non-dermatologic studies were used selectively to contextualize safety and pharmacology.</p><p><strong>Results: </strong>Across preclinical models, topical GZ21T reduced inflammation, pruritus, lesion burden, and tumor growth while promoting autophagy and suppressing pro-survival signaling pathways including MAPK, PI3K-AKT, mTOR-related pathways, Wnt, and ERBB signaling. In mycosis fungoides models, GZ17-6.02 increased apoptosis and enhanced tumor cell killing, including in combination with standard agents such as bexarotene. Safety data to date suggest favorable local tolerability, minimal systemic absorption in preclinical topical studies, and reversible liver enzyme elevations in oral phase 1 testing of GZ17-6.02.</p><p><strong>Conclusion: </strong>GZ21T represents a promising topical, multimodal therapeutic approach for inflammatory and premalignant or malignant skin disease. Further clinical studies are needed to confirm efficacy, define long-term safety, and establish its role relative to current standard therapies.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel.","authors":"Lauren DeBusk, Brooke Bartley, April W Armstrong, Christopher G Bunick, James Del Rosso, Seemal R Desai, Lawrence F Eichenfield, Boni E Elewski, Alexandra K Golant, Naiem Issa, Linda Stein Gold, Lisa Swanson, M Hunter Bohman, Angela Rosenberg, Darrell Rigel, Mark Lebwohl","doi":"10.25251/ha2gbq97","DOIUrl":"10.25251/ha2gbq97","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory skin diseases, including psoriasis and atopic dermatitis, require long-term management strategies that balance efficacy with safety. The 2025 American Academy of Dermatology guidelines encourage the judicious application of topical corticosteroids when their use is deemed necessary and for short durations of therapy. Recent availability of newer nonsteroidal topical therapies that are effective and safe, including for prolonged durations and on sensitive skin sites, has prompted a need for evidence-based guidance for clinicians in real-world practice. Tapinarof, a first-in-class, nonsteroidal aryl hydrocarbon receptor (AhR) agonist, was approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults and atopic dermatitis in patients aged 2 years and older in 2022 and 2025, respectively; however, its optimal place in therapy remains to be established.</p><p><strong>Objective: </strong>To develop expert consensus statements on the role of AhR agonists in the management of inflammatory skin diseases.</p><p><strong>Methods: </strong>A literature search produced 31 articles meeting inclusion criteria that were independently reviewed by an 11-member expert panel that convened on January 19, 2026. A modified Delphi process was used to develop 9 consensus statements.</p><p><strong>Consensus recommendations / key findings: </strong>AhR agonists represent a distinct therapeutic class with a unique multimodal mechanism involving immune modulation across Th1/Th2/Th17/Th22 pathways, skin barrier normalization, and antioxidant activity; tapinarof demonstrates a favorable safety profile with no restrictions on anatomic site, body surface area, or duration of use; tapinarof may be used concomitantly with systemic therapies; tapinarof is appropriate as both initial and long-term therapy for psoriasis in adults and atopic dermatitis in patients aged 2 years and older; and nonsteroidal topical therapies are preferred for chronic inflammatory skin diseases, particularly on the face and intertriginous areas.</p><p><strong>Conclusion: </strong>AhR agonist therapy offers a clinically meaningful, advanced nonsteroidal option that addresses key limitations of traditional topical therapies in inflammatory skin disease management.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A coincidental finding of adult-onset asymptomatic eccrine angiomatous hamartoma presenting as an erythematous patch.","authors":"Alice X Wen, Vicky Ren, Abdul Hafeez Diwan","doi":"10.25251/uesfw8fl","DOIUrl":"https://doi.org/10.25251/uesfw8fl","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An elusive diagnosis: Hemophagocytic variant of intravascular lymphoma masquerading as a drug eruption.","authors":"Hannah Hanania, Ted Rosen","doi":"10.25251/mbvr9i6v","DOIUrl":"https://doi.org/10.25251/mbvr9i6v","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-novo erythema nodosum leprosum necroticans as the initial presentation of multibacillary leprosy.","authors":"Gurudharshane R, Anita Marak, Evarisalin Marbaniang, Aniket Goswami, Shikha Thakur","doi":"10.25251/6qedmrre","DOIUrl":"https://doi.org/10.25251/6qedmrre","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of dermoscopy in patients with dark skin phototypes: Practices, challenges, and diagnostic value.","authors":"Meryeme Boutaarourt","doi":"10.25251/cbt3nw51","DOIUrl":"10.25251/cbt3nw51","url":null,"abstract":"<p><strong>Background: </strong>Dermoscopy is an essential diagnostic tool in dermatology; however, its application in patients with dark skin phototypes remains insufficiently explored.</p><p><strong>Objective: </strong>To assess dermatologists' practices, perceptions, and challenges regarding dermoscopy use in Fitzpatrick skin phototypes IV to VI.</p><p><strong>Methods: </strong>We conducted a cross-sectional study between February and May 2025. An online questionnaire was distributed to dermatologists practicing in various professional settings. A total of 64 participants were included.</p><p><strong>Results: </strong>Although dermoscopy was widely used, heterogeneous practices and a lack of structured training were identified. The main difficulties involved the interpretation of pigmented lesions, particularly melanoma, and the reduced visibility of vascular structures. Most respondents reported a lack of standardized criteria and adapted educational resources.</p><p><strong>Conclusion: </strong>These findings highlight the need for dedicated training programs and a more inclusive approach to dermoscopy in patients with dark skin.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous metastasis of ovarian adenocarcinoma: A unique vasculopathic presentation.","authors":"Chelsea Fathauer, Abigail Durbin, Janine Malone, Jae Jung","doi":"10.25251/kxppsd32","DOIUrl":"https://doi.org/10.25251/kxppsd32","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A scoping review: Community-based interventions for primary prevention of skin cancer.","authors":"Colin Burnette, Lachlan Anderson, Emily Deehan, John Meisenheimer, Yvonne Nong, Robert Dellavalle","doi":"10.25251/79p6zp62","DOIUrl":"10.25251/79p6zp62","url":null,"abstract":"<p><strong>Background: </strong>Skin cancer remains one of the most preventable yet prevalent malignancies worldwide, with non-melanoma and melanoma skin cancers ranking among the top 5 and top 20 most common cancers, respectively. Rising incidence rates in countries such as the United States and Australia have been linked to high ultraviolet (UV) radiation exposure and modifiable behavioral risk factors. Public health efforts increasingly emphasize sun safety education to reduce UV exposure and mitigate long-term cancer risk.</p><p><strong>Objective: </strong>To summarize the current research landscape of intervention strategies for the primary prevention of skin cancer and the study designs used to evaluate these efforts.</p><p><strong>Methods: </strong>We conducted a scoping review following PRISMA-ScR guidelines across PubMed, CINAHL, Embase, Cochrane Library, and PsycInfo. Included studies assessed original sun safety programs implemented in school, community, and healthcare settings, focusing on behavior change, accessibility, and long-term impact.</p><p><strong>Results: </strong>This review highlights the variability in intervention design and underscores the need for comprehensive, evidence-based strategies that integrate education with accessible resources.</p><p><strong>Conclusion: </strong>Strengthening these efforts is essential to improving sun safety practices and reducing the global burden of skin cancer.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Café-au-lait macules in a cohort of Greek children genetically diagnosed with neurofibromatosis type 1: Prognostic significance beyond their diagnostic relevance.","authors":"Alexios Alexopoulos, Dimitrios Ntokos, Despina Briana, Roser Pons, Christina Stefanaki, Louiza Kontara, Christina Kanaka-Gantenbein, Lamprini Nasi","doi":"10.25251/10.25251/t1jlta74","DOIUrl":"10.25251/10.25251/t1jlta74","url":null,"abstract":"<p><strong>Background: </strong>Café-au-lait macules (CALMs) are often the earliest visible sign of neurofibromatosis type 1 (NF1), a genetic disorder with marked clinical variability. Early characterization of CALM patterns may aid in anticipating systemic disease burden.</p><p><strong>Objective: </strong>To analyze the early appearance, anatomical distribution, and number of CALMs in children with genetically confirmed NF1 and explore associations with central nervous system (CNS) and skeletal manifestations.</p><p><strong>Methods: </strong>We retrospectively reviewed children with genetically confirmed NF1 at a tertiary pediatric hospital in Athens, Greece (2018-2023). Demographic data, CALM count and distribution, mutation type, and systemic involvement were recorded. CALMs were documented through standardized dermatologic assessment and clinical photography. Statistical correlations were evaluated using nonparametric tests.</p><p><strong>Results: </strong>Sixty-three children (33 males, 30 females; mean age 7.5 ± 4.6 years) were included. All had more than 6 CALMs (mean 18.1 per child), most frequently on the thoracic region (53.6%). In 38.1% of patients, more than 6 CALMs were present by 6 months; among those with 6 or fewer at 6 months, 94.9% exceeded this threshold by 24 months. Children with 7-12 CALMs at 12 months had significantly higher frequencies of CNS and skeletal manifestations (<i>P</i> < .05).</p><p><strong>Conclusion: </strong>CALMs were predominantly thoracic and showed the steepest increase between 6 and 12 months. Children with 7-12 CALMs at 12 months had greater systemic involvement, supporting early, risk-adapted surveillance strategies in pediatric NF1.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}